Journal
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Volume 24, Issue 5, Pages 1294-1298Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2014.01.066
Keywords
P2Y(1) antagonist; Spiropiperidinylindolines; Antiplatelet agent
Categories
Ask authors/readers for more resources
Spiropiperidine indoline-substituted diaryl ureas had been identified as antagonists of the P2Y(1) receptor. Enhancements in potency were realized through the introduction of a 7-hydroxyl substitution on the spi-ropiperidinylindoline chemotype. SAR studies were conducted to improve PK and potency, resulting in the identification of compound 3e, a potent, orally bioavailable P2Y(1) antagonist with a suitable PK profile in preclinical species. Compound 3e demonstrated a robust antithrombotic effect in vivo and improved bleeding risk profile compared to the P2Y(12) antagonist clopidogrel in rat efficacy/bleeding models. (C) 2014 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available